Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Ustekinumab SC
DRUG
2 trials
Sponsors
Janssen Research & Development, LLC
Conditions
Colitis, Ulcerative
Inflammatory Bowel Diseases
Lupus Erythematosus, Systemic
Phase 2
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Completed
NCT02349061
Janssen Research & Development, LLC
Lupus Erythematosus, Systemic
Start: 2015-10-15
End: 2019-03-13
Updated: 2020-03-24
Phase 3
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Completed
NCT02407236
Janssen Research & Development, LLC
Colitis, Ulcerative, Inflammatory Bowel Diseases
Start: 2015-07-10
End: 2021-11-30
Updated: 2025-04-29
Related Papers
P0366 Computer vision endoscopy scoring for ulcerative colitis disease severity (ARGES-CMES): A comparison between adult and paediatric clinical trials
Journal of Crohn s and Colitis
2026-01-01
Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 <scp>UNIFI</scp> Study of Ustekinumab in Ulcerative Colitis
Alimentary Pharmacology & Therapeutics
2025-07-16
2 citations
P0559 Endoscopic healing at 1-year and association with long-term quality of life in ulcerative colitis: A pooled clinical trial analysis adjusting for 1-year clinical remission status
Journal of Crohn s and Colitis
2025-01-01
Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis.
2024-10-04
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
2024-08-01
18 citations
P280 Comparative responsiveness of disease activity indices in moderately-to-severely active Ulcerative Colitis: a post-hoc analysis of the UNIFI trial
Journal of Crohn s and Colitis
2024-01-01
1 citations
P928 "Metabolism and Response to Stress" (MARS) gene signatures reveal heterogeneity in patients with Ulcerative Colitis and identify characteristics of patients with increased response to therapy
Journal of Crohn s and Colitis
2024-01-01
P213 ArgesMES: A high-performance, generalizable AI model for scoring Ulcerative Colitis severity from endoscopy videos
Journal of Crohn s and Colitis
2024-01-01
P294 ArgesUCEIS: A high-performance, generalizable AI models for scoring Ulcerative Colitis Endoscopic Index of Severity (UCEIS) component scores in endoscopy videos
Journal of Crohn s and Colitis
2024-01-01
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study
The American Journal of Gastroenterology
2023-12-14
30 citations
Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis
Precision Clinical Medicine
2023-07-14
4 citations
P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
Journal of Crohn s and Colitis
2023-01-30
3 citations
P390 Ustekinumab modulates IL-12 and IL-23-related cell type-specific inflammatory transcriptional states in Ulcerative Colitis induction therapy
Journal of Crohn s and Colitis
2023-01-30
DOP73 Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)
Journal of Crohn s and Colitis
2023-01-30
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial
Clinical Gastroenterology and Hepatology
2022-03-08
33 citations
Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study
The Journal of Rheumatology
2021-12-01
27 citations
P388 Agreement between locally and centrally reviewed Mayo endoscopic subscores in the UNIFI study of ustekinumab in patients with Ulcerative Colitis
Journal of Crohn s and Colitis
2021-05-01
1 citations
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Intestinal Research
2020-11-30
22 citations
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy
Alimentary Pharmacology & Therapeutics
2020-10-21
65 citations
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
Inflammatory Bowel Diseases
2020-09-23
112 citations
5 more papers not shown